Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?Pharmacology Published on 2020-05-262022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory syndrome addition antiviral activity approved clinical Clinical improvement clinical trial conducted Coronavirus-2 COVID-19 double blind double-blind Ebola Efficacy Evidence exhibited faster global public health globe GS-5734 in vitro in vitro activity in vivo Infection MERS-CoV Novel coronavirus open label option Phase 3 Placebo placebo controlled trial Prevent preventive measure Randomized RdRP Remdesivir RNA RNA polymerase SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 strain Science severe COVID-19 patient statistically significant Strains therapeutic option therapy treat Trial Vaccine WHO Solidarity trial Wuhan, China [DOI] 10.3389/fphar.2020.00791 PMC 바로가기 [Article Type] Pharmacology
Core Outcome Set for Clinical Trials of COVID-19 Based on Traditional Chinese and Western MedicinePharmacology Published on 2020-05-252022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] antibody Blood blood gas analysis Blood oxygen saturation C-reactive protein Chinese clinical Clinical efficacy Clinical outcome clinical symptom clinical trial clinical trials conducted Consensus core Core outcome set COVID-19 DelPhi development disease eligible etiology heterogeneity IMPROVE Inflammatory limitation Lymphocytes mechanical ventilation Medicine methodology mild-to-moderate disease Nurses outcome oxygen pandemic PaO2/FiO2 ratio parameter participated Patient Pneumonia Severity Index Prevalence progression protocol questionnaire Research Respiratory outcome Result SARS-CoV-2 severe disease Study protocol Symptom systematic review TCM temperature Traditional Traditional Chinese medicine Viral load virus vital sign Western medicine [DOI] 10.3389/fphar.2020.00781 PMC 바로가기 [Article Type] Pharmacology
Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension studyarticle Published on 2020-05-252024-09-02 Journal: Journal of Neurology [Category] 대상포진, [키워드] clinical trial Daclizumab beta Relapsing–remitting multiple sclerosis selected [DOI] 10.1007/s00415-020-09835-y PMC 바로가기 [Article Type] article
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial중증 COVID-19 성인 환자에 대한 정맥 주사 렘데시비르의 효능 및 안전성 평가: 무작위 배정, 이중 맹검, 위약 대조, 다기관 임상 3상 연구 프로토콜Study Protocol Published on 2020-05-242022-09-10 Journal: Trials [Category] MERS, SARS, 비임상, [키워드] Administered Administrative information Adult patients Antiviral assigned asymptomatic infection breath category caused China Clinical efficacy Clinical improvement clinical manifestation clinical manifestations clinical status clinical trial concern conducted coronavirus disease Coronavirus disease 2019 Coronavirus infections Coronaviruses COVID-19 COVID-19 virus death defined discharge double-blind Efficacy Efficacy and safety Emergency enrolment event futility GS-5734 Health Organization highly pathogenic hospital in vitro in vivo experiments include Infection inhibitory inhibitory effect Inhibitory effects interim analysis Intravenous remdesivir intravenously laboratory-confirmed MERS-CoV Mild multicentre nucleoside Ordinal Scale Patient Phase 3 Placebo placebo-controlled placebo-controlled trial Pneumonia primary endpoint protocol Public public health emergency randomization Randomized Randomly Remdesivir reported required Respiratory failure SARS-CoV SARS-CoV-2 virus severe COVID-19 severe pneumonia severe viral pneumonia Spread Standard Study protocol Symptoms Treatment Trial Trial registration upper respiratory symptoms Viral Viral pneumonia virus infection World Health Organization Wuhan [DOI] 10.1186/s13063-020-04352-9 PMC 바로가기 [Article Type] Study Protocol
Emerging Pharmaceutical Treatments of Novel COVID-19: A ReviewEmergency Medicine Published on 2020-05-242022-10-31 Journal: Cureus [Category] COVID-19, [키워드] ACE2 receptors Admission Antimicrobials antivirals approaches candidate drug Candidates clinical trial clinical trials COVID-19 deaths drug Efficacy global pandemic Infectious disease inhibiting viral replication mechanism mechanism of action novel Occurrence pharmaceutical Pharmacology Prevent preventative measure Research review SARS-CoV-2 social distancing Treatment virus [DOI] 10.7759/cureus.8260 PMC 바로가기 [Article Type] Emergency Medicine
Review of trials currently testing treatment and prevention of COVID-19Systematic Review Published on 2020-05-232022-10-04 Journal: Clinical microbiology and infection : the official [Category] MERS, SARS, 신약개발, 임상, 치료법, [키워드] Abstract age analysed Anti-inflammatory antivirals applied assist category Chinese clinical clinical trial clinical trials country COVID-19 COVID-19 case COVID-19 pandemic effort eligibility criteria European evaluated Evidence excluded Image immunomodulators Inclusion interquartile range Intervention investigated Major management median Novel coronavirus Numerous objective open label participant Patient care performed physician Pneumonia Potential treatment prevention prevention of COVID-19 promote Randomized Randomized controlled trial Registered registry Research researcher Result retrieved review SARS-CoV-2 searched Study design therapeutic Treatment Trial union withdrawn [DOI] 10.1016/j.cmi.2020.05.019 PMC 바로가기 [Article Type] Systematic Review
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) Reviews Published on 2020-05-222022-10-05 Journal: Leukemia [Category] SARS, 유전자 메커니즘, 임상, [키워드] Administered Allogeneic biochemical bortezomib Cancer Cell clinical trial Community Comorbidities Complication Consensus consensus paper country COVID-19 COVID-19 infection COVID-19 pandemic Dexamethasone disease drug interaction early diagnosis end organ damage European event Hospital admission hygiene Immunocompromised increased risk infections International Local Multiple myeloma Myeloma Nasopharyngeal swab network no symptom Older age oral Patient Patient education PCR test positive PCR test provided quarantine regimen risk SARS-CoV-2 Severe COVID-19 Infection social distancing measures Spread Surveillance symptomatic COVID-19 disease therapeutic decision Treatment [DOI] 10.1038/s41375-020-0876-z [Article Type] Reviews
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and CareOncology Published on 2020-05-222022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] Cancer clinical trial Conducting COVI-19 phase Phase I (drug development) SARS - CoV-2 Science [DOI] 10.3389/fonc.2020.00926 PMC 바로가기 [Article Type] Oncology
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of ItalyResearch Article Published on 2020-05-212022-10-31 Journal: Future Oncology [Category] COVID-19, MERS, SARS, [키워드] applied Cancer Care clinical trial clinical trials coronavirus disease COVID-19 COVID-19 infection Critical domain Fighting health worker healthcare Healthcare workers Infection Italian Italy material measure Medical doctor medical oncology departments Nurse occurred oncological centresoncological patients oncology Patient patients question questionnaire Rate reduce risk of COVID-19 risk reduction Spread survey [DOI] 10.2217/fon-2020-0358 PMC 바로가기 [Article Type] Research Article
Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells대유행 완화제 후보의 삼자 조합: 인간 세포에서 SARS-CoV-2 표적의 게놈 유도 추적으로 정의된 COVID-19 대유행의 표적 완화를 위한 약제의 비타민 D, 케르세틴 및 에스트라디올 매니페스트 특성Article Published on 2020-05-212022-09-10 Journal: Biomedicines [Category] 비임상, [키워드] 2019 coronavirus disease ACE2 activity Affect agent Alter analyses Analysis breath build candidate cell types cellular clinical trial clinical trials Combination condition contribute coronavirus coronavirus disease Coronavirus infection COVID-19 COVID-19 pandemic deficiency disease drug drugs drugs and medicinal substance repurposing Effect elements enrichment eriodictyol estradiol experiment expression expression profiling facilitate Follow-up function functions furin FURIN expression FURIN gene GATA5 gene expression profile Gene expression profiles gene expression signature Gene Set Enrichment Analyses gene silencing Genomics GSEA HIF1a high mortality HMGA2 HNF4A Human human body human cell human cells human gene human genes hypothetical identify Immediate Immune cell immune cells Immunosuppression Impact infect Infection Inference inhibitor inhibitors of SARS-CoV-2 INSIG1 interfere Intervention intrinsically Luteolin majority male Mitigation mitigation approaches molecular Mortality observation observational study observations Older overexpression pandemic Panel Patient persistence present property Protein Protein target protein targets Proteins quercetin Randomized randomized clinical trial Regulatory reported repressor required RUNX1 SARS-CoV-2 SARS-CoV-2 coronavirus SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 proteins SARS-CoV-2 viral selective severity SFTPC smoking Spread SUMMIT drug-docking screen target targets Testosterone the SARS-CoV-2 tissues tracing Transgenic mouse Treatment upstream utility Viral Viral protein Viral proteins virus Vitamin D vitamin D deficiency website [DOI] 10.3390/biomedicines8050129 PMC 바로가기 [Article Type] Article